, Volume 470, Issue 2, pp 366-372
Date: 21 Jun 2011

Second-generation Modular Acetabular Components Provide Fixation at 10 to 16 Years

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

First-generation modular titanium fiber-metal-coated acetabular components had high rates of wear, pelvic osteolysis, and liner dissociation. Second-generation components were designed to reduce the incidence of these problems but it is unclear whether the changes achieved these goals.

Questions/purposes

We asked the following questions: (1) Is the risk of revision surgery for loosening, wear, or liner dissociation low with the second-generation acetabular component? (2) Is the rate of pelvic osteolysis low? (3) Can the liner be exchanged without bone cement?

Methods

We retrospectively reviewed prospectively collected data from 99 patients (118 hips) undergoing THAs with one second-generation modular titanium acetabular component with routine screw fixation and conventional polyethylene. The minimum followup was 10 years (mean, 12 years; range, 10–16 years). We obtained Harris hip scores and examined radiographs for loosening and osteolysis.

Results

At last followup, all acetabular components were well fixed and no titanium shell had been revised or removed. No liner had dissociation. At most recent followup, the mean Harris hip score was 89. We observed pelvic osteolysis in eight hips (7%). There were three reoperations for dislocation (head-liner exchange only) and three loose femoral components revised. Two liners (at 11 and 14 years) were exchanged for wear-pelvic osteolysis.

Conclusions

This second-generation modular titanium fiber-metal-coated acetabular component with screw fixation had no loosening, no liner dissociation, and a low rate of pelvic osteolysis at 10 to 16 years. Liner exchange is practical without use of cement. We continue to use this component with highly crosslinked polyethylene liners.

Level of Evidence

Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

One of the authors (PFL) is a member of the speakers’ bureau of Zimmer, and his institution received research support from Zimmer for a different study.
Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.